Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytosorbents Cor (CTSO)

Cytosorbents Cor (CTSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,237
  • Shares Outstanding, K 62,804
  • Annual Sales, $ 35,590 K
  • Annual Income, $ -20,720 K
  • EBIT $ -17 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.28
  • Price/Sales 1.32
  • Price/Cash Flow N/A
  • Price/Book 5.21
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.04 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Products

Options Overview Details

View History
  • Implied Volatility 342.96% (+59.85%)
  • Historical Volatility 92.25%
  • IV Percentile 34%
  • IV Rank 23.68%
  • IV High 1,215.56% on 12/02/25
  • IV Low 72.23% on 12/13/24
  • Expected Move (DTE 8) 0.0340 (4.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 315
  • Open Int (30-Day) 311
  • Expected Range 0.6760 to 0.7440

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6000 +18.33%
on 11/20/25
0.8500 -16.47%
on 11/24/25
+0.0121 (+1.73%)
since 11/11/25
3-Month
0.6000 +18.33%
on 11/20/25
1.0200 -30.39%
on 10/03/25
-0.2433 (-25.52%)
since 09/11/25
52-Week
0.6000 +18.33%
on 11/20/25
1.6100 -55.90%
on 02/14/25
-0.1707 (-19.38%)
since 12/11/24

Most Recent Stories

More News
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

PRINCETON, N.J. , Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

PRINCETON, N.J. , Nov. 17, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
CytoSorbents: Q3 Earnings Snapshot

CytoSorbents: Q3 Earnings Snapshot

CTSO : 0.7100 (+8.13%)
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

PRINCETON, N.J. , Nov. 13, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

PRINCETON, N.J. , Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J. , Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

PRINCETON, N.J. , Oct. 28, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 0.7100 (+8.13%)
Cytosorbents Faces Nasdaq Non-Compliance Notice

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cytosorbents...

CTSO : 0.7100 (+8.13%)
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit...

CTSO : 0.7100 (+8.13%)
CytoSorbents Provides DrugSorb-ATR Regulatory Update

PRINCETON, N.J. , Sept. 16, 2025 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and...

CTSO : 0.7100 (+8.13%)

Business Summary

CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product...

See More

Key Turning Points

3rd Resistance Point 0.7808
2nd Resistance Point 0.7554
1st Resistance Point 0.7060
Last Price 0.7100
1st Support Level 0.6312
2nd Support Level 0.6058
3rd Support Level 0.5564

See More

52-Week High 1.6100
Fibonacci 61.8% 1.2242
Fibonacci 50% 1.1050
Fibonacci 38.2% 0.9858
Last Price 0.7100
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar